pirfenidone
pirfenidone: 9 clinical trials tracked.
pirfenidone evidence translation
What we can confirm
9 tracked trials
What it means
What to watch
Prepared research question
What is verified about pirfenidone, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (9)
Evaluation of Pirfenidone as a Novel Therapeutic Strategy Against Chronic Pancreatitis.
Primary endpoint: Number of Participants With at Least One Grade 3 or Grade 4 Adverse Event as Assessed by CTCAE Version 5.0
A Randomized, Double-Blind, Head-to-Head Phase 3 Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone at 52 Weeks in Adults With Idiopathic Pulmonary Fibrosis (SURPASS-IPF)
Primary endpoint: Absolute change in forced vital capacity (FVC) measured in mL
A Multicenter, Parallel, Randomized, Placebo (Double-blind) and Pirfenidone (Open-label) Controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of HEC585 Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Primary endpoint: Change in FVC from baseline at 52 weeks (mL)
A Phase 1, Two-Part, Open-Label Drug-Drug Interaction Study to Evaluate the Steady State Pharmacokinetics and Safety Following Co-Administration of Nalbuphine Extended-Release Tablets (NAL ER), and Pirfenidone or Nintedanib in Healthy Adult Subjects
Primary endpoint: Maximum Plasma Concentration (Cmax) of NAL ER, Pirfenidone, and Nintedanib
Evaluation of Pirfenidone as a Therapy in Patients With Predicted Moderate to Severe Acute Pancreatitis
Primary endpoint: Development of Anticipated or Un-anticipated Adverse Events (Class 3 or 4)
A Randomized Double-blind, Four-Arm Active and Placebo-controlled Dose-Finding Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Primary endpoint: Rate of decline in Forced Vital Capacity over 26 weeks (Part A)
A Phase 1, Double-Blind, Randomized, Crossover Study in Older Healthy Subjects to Compare the Safety, Tolerability, and Pharmacokinetics of Lyt-100 (Deupirfenidone) to Pirfenidone
Primary endpoint: Part 1: Cmax of BID deupirfenidone versus TID pirfenidone
A Phase II, Multi-center, Randomized, Placebo-controlled (Double-blind Design), Active Comparator-controlled (Open-label Design), Parallel-group, Dose-finding Study, to Evaluate the Efficacy and Safety of HEC585 Tablets in Patients With IPF
Primary endpoint: Change from Baseline to Week 24 in %FVC compared with placebo
A Single-center, Open-label Study Designed to Assess the Drug-drug Interaction of HEC585 And Pirfenidone/Nintedanib In Healthy Subjects
Primary endpoint: Area under the curve from 0 to 24 hours [AUC (0~24)]